Orbimed Advisors LLC lessened its position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 44.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 821,400 shares of the company's stock after selling 659,200 shares during the quarter. Orbimed Advisors LLC owned about 1.16% of Nkarta worth $2,045,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of Nkarta by 252.1% in the third quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company's stock valued at $4,806,000 after purchasing an additional 761,349 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Nkarta by 4.1% in the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock worth $561,000 after buying an additional 8,883 shares in the last quarter. Barclays PLC grew its stake in shares of Nkarta by 161.4% in the 3rd quarter. Barclays PLC now owns 232,566 shares of the company's stock worth $1,051,000 after buying an additional 143,608 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Nkarta in the 4th quarter worth about $31,000. Finally, American Century Companies Inc. raised its position in shares of Nkarta by 8.8% during the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock valued at $226,000 after buying an additional 7,378 shares in the last quarter. Institutional investors own 80.54% of the company's stock.
Nkarta Trading Up 4.7%
Shares of NASDAQ:NKTX opened at $2.02 on Tuesday. Nkarta, Inc. has a 12 month low of $1.31 and a 12 month high of $8.23. The company has a market capitalization of $143.34 million, a price-to-earnings ratio of -1.07 and a beta of 0.81. The firm's 50-day moving average is $1.79 and its 200 day moving average is $2.23.
Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. As a group, equities analysts forecast that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently commented on NKTX shares. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Nkarta in a research note on Wednesday, April 9th. Finally, Stifel Nicolaus cut their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $14.83.
Check Out Our Latest Stock Analysis on Nkarta
About Nkarta
(
Free Report)
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Featured Stories
Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
